Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The ...

Despite advances in treatment for inflammatory bowel disease, more than 55% of patients report medication delays, mostly due ...

Samsara is the IBD Stock of the Day ahead of its Q4 earnings report due March 6. Samara stock has forged a cup base, rebounding from a sell-off.

The most common reason for delaying or not receiving care was not getting an appointment when they needed one, cited by 39% of respondents. More than half (56%) of patients reported delays in ...

A study led by the University of Birmingham found that vancomycin, a commonly used antibiotic for diarrhea, could effectively ...

The inflammatory bowel disease (IBD), develops due to an incurable autoimmune liver disease called primary sclerosing ...

Brady Cl A saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 72. Please watch the ...

In terms of fundamentals, Omnicell has posted three quarters of increasing earnings growth. Revenue growth has also moved ...

A recent major OECD report has warned of a looming crisis in the European health workforce. In the third in our series on the ...

An antibiotic used to treat infective diarrhoea could be an effective drug for a type of inflammatory bowel disease, a new study has found.

Many of us pay attention to the foods we're putting in our bodies – asking ourselves whether they're nutritious and healthy ...

A new report into the state of inflammatory bowel disease in Australia has revealed rates of the life long disease in the ...